UthPeak NMNH for Safety and Tolerability in Healthy Adults

This study investigates the safety and how the body processes a compound called UthPeak NMNH, which is a form of nicotinamide mononucleotide. It involves 80 healthy adults who meet specific health criteria. The aim is to understand if different doses of NMNH, taken orally over 90 days, are safe and well-tolerated. This research is important as it could provide insights into how NMNH might support health and well-being by evaluating changes in NAD+ levels, which are linked to energy production and cellular health. Participants are divided into four groups, each receiving either a placebo or different doses of NMNH (125 mg, 250 mg, or 500 mg). They take the supplement daily and have their NAD+ levels, physical abilities, and quality of life assessed at the start, middle, and end of the study. Blood samples are collected at various times after the first dose to measure NAD+ levels, focusing on how the body absorbs and processes the supplement. Regular health checks and monitoring for side effects ensure participant safety.